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ABSTRACT (500 words) 
Purpose: 
99m
Tc is the radionuclide most widely used in diagnostic nuclear medicine. It is readily 
available from 
99
Mo/
99m
Tc generators as a β-decay product of the 99Mo (T½=66 h) parent nuclide. 
The latter is obtained as a fission product in nuclear reactors by neutron-induced reactions on highly 
enriched uranium. Alternative production routes, such as direct reactions using proton beams on 
specific target materials [e.g. 
100
Mo(p,2n)
99m
Tc] are a reliable and relatively cost-effective method. 
However, the results of the LARAMED (Laboratory of Radionuclides for Medicine) project 
research from the Legnaro National Laboratories of the National Institute for Nuclear Physics 
(LNL-INFN), showed that the extracted 
99m
Tc from the proton-bombarded 
100
Mo-enriched
 
target 
contains small quantities of several technetium radioisotopes (
93m
Tc, 
93
Tc, 
94
Tc, 
94m
Tc, 
95
Tc, 
95m
Tc 
96
Tc and 
97m
Tc).  
The aim of this work was to determine the patient dose increase (DI) due to the contribution of Tc-
radioisotopes generated as impurities, after the administration of four radiopharmaceuticals 
prepared with cyclotron-produced 
99m
Tc (CP-
99m
Tc). 
Methods: Four 
99m
Tc-radiopharmaceuticals (pertechnetate, sestamibi, hexamethylpropylene-amine 
oxime (HMPAO) and disodium etidronate (HEDP)), were considered in this study. The biokinetic 
models reported by the International Commission on Radiological Protection (ICRP) for each 
radiopharmaceutical were used to determine the main source organs and to calculate the number of 
disintegrations that occurred in each source organ (Nsource) for each Tc-radioisotope present in the 
CP-
99m
Tc solution. Then, equivalent dose in the main organs and effective dose were calculated for 
each Tc-radioisotope with the OLINDA/EXM software versions 1.1 and 2.0, using the calculated 
Nsource and the adult male phantom as program inputs. Finally, the total effective dose produced by 
all Tc-radioisotopes present in the CP-
99m
Tc solution was calculated at five different times after the 
end of bombardment (EOB), using 
100
Mo-enriched (i.e. 99.05 %) metallic target, and compared 
with the effective dose delivered by the generator-produced-
99m
Tc. 
Results: In all cases, the total effective DI of CP-
99m
Tc-radiopharmaceuticals, calculated with both 
versions of the OLINDA software, remained within the 10% limit from 6 up to 12 h after EOB.
 
94m
Tc and 
93m
Tc are the Tc-radionuclides with the highest concentration in the CP-
99m
Tc solution at 
EOB. However, their contribution to DI 6 h after EOB is minimal, due to of their short half-life. 
Although their concentration in the CP-
99m
Tc solution is 5 times less than 
94m
Tc and 
93m
Tc at the 
EOB,
 
the radioisotopes with the largest contribution to the effective DI are 
96
Tc, followed by 
95
Tc 
and 
94
Tc, due to the type of their emissions and relatively long half-life.  
Conclusion: The increase in the patient radiation dose caused by the other technetium-nuclides
 
contained in CP-
99m
Tc produced as described in this paper, is quite low. Therefore, it was concluded 
that although in the CP-
99m
Tc solution the concentrations of two radionuclides, 
94
Tc and 
95
Tc, are 
outside the limits established by the European Pharmacopoeia, it could be used in routine nuclear 
medicine diagnostic studies, but would have to be administered from 6 to 12 h after the EOB to 
maintain the effective DI within the 10 % limit. 
Keywords: 
cyclotron-produced 
99m
Tc, 
99m
Tc-radiopharmaceuticals effective dose, Tc-dosimetry, Dose Increase 
(DI). 
  
1. INTRODUCTION 
Technetium-99m is the radionuclide most widely used in diagnostic nuclear medicine. Sodium 
pertechnetate is used as raw material to prepare more than twenty 
99m
Tc-radiopharmaceuticals 
employed for the detection of diverse physiological and pathological conditions such as myocardial 
perfusion, kidney and brain disorders as well as bone metastases
1
. The radioisotope is readily 
available in hospitals from 
99
Mo/
99m
Tc generators, as β-decay product of 99Mo, which in turn, is a 
selected and purified fission product of weapon-grade highly enriched uranium (HEU-WG), special 
targets in nuclear reactors. However, the majority of 
99
Mo isotope global production is the work of 
less than seven nuclear reactor facilities worldwide and most of them are close to being 
permanently shut down at the end of their running periods (more than 50 years of operation). 
Therefore, alternative production routes for both 
99
Mo and 
99m
Tc nuclides are currently being 
evaluated
2-4
. Among them, the use of cyclotrons to produce either 
99
Mo or 
99m
Tc is one of the most 
interesting and promising approaches
5,6
. 
Experimental studies on 
99m
Tc production by cyclotrons were initiated within the framework of the 
TECHN_OSP/LARAMED (Laboratory of Radionuclides for Medicine) research project, by the 
Legnaro National Laboratories at the National Institute for Nuclear Physics, Italy (LNL-INFN)
7
. A 
PETtrace GE cyclotron was used to obtain cyclotron-produced 
99m
Tc (CP-
99m
Tc), using the 
100
Mo(p,2n)
99m
Tc reaction on 
100
Mo-enriched (i.e. 99.05 %) metallic targets, the isotopic 
composition of the enriched molybdenum used was a good compromise between enriched and cost
8
. 
99m
Tc was extracted and purified from the irradiated targets by solvent extraction through the 
Methyl-Ethyl Ketone (MEK) method, using a self-developed automated module with an efficiency 
greater than 90%
9
. 
Results demonstrated that the direct reaction method is reliable and a relatively cost-effective option 
to produce 
99m
Tc. However, gamma-ray spectrometry analyses of the obtained purified 
99m
Tc 
solutions demonstrated the presence of small quantities of several technetium radioisotopes, such as 
93
Tc, 
93m
Tc,
 94
Tc, 
94m
Tc,
 95
Tc, 
95m
Tc, 
96
Tc and 
97m
Tc
8
. It has been reported by previous studies that the 
abundance of these contaminant nuclides is basically dependent on some changing factors, such as 
the target’s isotopic composition, beam energy level, target thickness, irradiation time and time span  
from irradiation to administration
10,11
. Despite the presence of  technetium isotopes in the solution, 
all radiopharmaceuticals labelled with CP-
99m
Tc showed no differences in the labelling efficiency, 
radiochemical purity and biological behaviour when compared to the radiopharmaceuticals labelled 
with generator-produced 
99m
Tc (GP-
99m
Tc)
12,13
. It was also demonstrated that scatter-corrected 
images of rats, obtained after administration of radiopharmaceuticals for myocardial perfusion and 
bone imaging labelled with CP-
99m
Tc and GP-
99m
Tc, were comparable
12,14
. Selivanova et al 
confirmed these results demonstrating no difference in whole body biodistribution images of 
patients, after administration of sodium pertechnetate produced by cyclotron and generator
15
. 
The main problem with the technetium impurities is that they contribute to the radiation dose of the 
patient
10
. Thus, the European Pharmacopoeia Commission established a monograph of sodium 
pertechnetate obtained by proton irradiation of highly-enriched molybdenum-100 targets, in order to 
set the limits of radionuclide impurities for the solutions used in clinical diagnosis
16
.  
The aim of this work was to determine the increase of the total effective dose in patients due to the 
contribution of all Tc-radionuclides produced as impurities. Effective dose increase was calculated 
for four radiopharmaceuticals prepared with 
99m
Tc produced by a PETtrace GE cyclotron, 
evaluating five times points after the end of bombardment (EOB), in order to find the best period 
when the CP-
99m
Tc radiopharmaceuticals could be used.  
 
2. MATERIALS AND METHODS 
Four of the 
99m
Tc-radiopharmaceuticals most used in the clinical diagnosis at the Nuclear Medicine 
Department of the Veneto Institute of Oncology IOV-IRCCS were considered for this study: 
sodium pertechnetate, used in clinical diagnosis of thyroid function and morphology; disodium 
etidronate (HEDP), a phosphonate commonly used for defining bone metastasis in cancer patients; 
hexamethylpropyleneamine oxime (HMPAO), used as a tracer of brain function and sestamibi 
(MIBI), widely used in cardiac scans for diagnosis of heart disease. The total effective dose 
increases 
 were assessed considering the administration of the four radiopharmaceuticals labelled with both 
GP-
99m
Tc and CP-
99m
Tc produced by the alterative 
100
Mo(p,2n) reaction route, through a GE 
PETtrace cyclotron and using enriched (99.05%) molybdenum-100 metallic targets.  
 
2.1 Number of disintegrations in the source organs  
The biokinetic models published by the International Commission on Radiological Protection 
(ICRP) were used to determine the main source organs for each radiopharmaceutical. Pertechnetate 
and HEDP biokinetic models were obtained from ICRP publication 53: “Radiation dose to patients 
from radiopharmaceuticals”17; HMPAO and MIBI models were obtained from publication 80 
(addendum 2 to ICRP publication 53)
18
. The cumulated activities, or number of disintegrations that 
occurred in the source regions over time (Nsource), were calculated for each radionuclide taking into 
account the related biological elimination constant for each source organ reported by the ICRP 
radiopharmaceutical models.  
The number of disintegrations in the bladder (Nb) for each radionuclide was calculated for all 4 
radiopharmaceuticals using the kidney-bladder model presented in ICRP publication 106 
(addendum 3 to ICRP publication 53)
19
, with the following formula: 
𝑁𝑏 = 𝑓𝑠 ∑ 𝑎𝑖
𝑖
[
1 − exp(−𝝀𝒑𝒕𝒃)
𝝀𝒑 
−
1 − exp(−(𝝀𝒊 + 𝝀𝒑)𝒕𝒃)
𝝀𝒊 + 𝝀𝒑 
 ] [
1
1 − exp(−(𝝀𝑖 + 𝝀𝑝)𝒕𝒃)
] 
where fs is the fractional distribution to organ or tissue, ɑi is the fraction of fs eliminated with the 
corresponding  biological constant λi, λp is the physical decay constant, and tb is the bladder filling 
and voiding interval (considered a constant of 3.5 h in adults).   
Kidney and bladder are the organs that received the highest dose after administration of 
phosphonates such as HEDP, because they are mainly eliminated by the kidney. Thus, the number 
of disintegrations in the kidney (NK) was calculated using the kidney-bladder model from ICRP 53 
with the following formula (considering both kidney uptake and the activity that passes through this 
organ due to excretion): 
𝑁𝐾 = 𝑓𝐾 [
1 − exp(−𝝀𝒑𝒕𝑲) 
𝝀𝒑 
] ∑ 𝑎𝑖
𝑖
𝝀𝑖
𝝀𝑖 + 𝝀𝑝
 
where fK is the kidney fractional distribution and tK is the mean transit time of phosphonates in the 
kidney. The other 3 radiopharmaceuticals are eliminated predominantly by the gastro-intestinal (GI) 
system; therefore, the number of disintegrations that occurred in this tract were calculated using the 
GI model of the OLINDA/EXM 1.1 software
20
, which is based on the ICRP 30 GI model
21
.  
 
2.1 Dose Calculations 
Each organ’s absorbed dose was calculated for each Tc radioisotope with the OLINDA/EXM 1.1 
and OLINDA/EXM 2.0 software codes. The OLINDA version 1.1 makes use of anthropomorphic 
phantoms based on the Oak Ridge models, which employs geometrical shapes to define the organs 
and calculates the effective dose using the tissue weighting factors recommended by ICRP 60
22
. In 
version 2.0, the geometrical models were replaced by the realistic NURBS-type models, based on 
the recent standardized masses defined by the ICRP in its publication 89
23
, and the tissue weighting 
factors were implemented in accordance with the recommendations of  ICRP 103
24
.  
Both versions of OLINDA/EXM software use the RADAR dose system and calculate the 
equivalent dose in each organ according to the general equation: 
__
D target←source = Nsource × DF target←source 
where Nsource is the number of disintegrations that occur in the source organ per unit of activity 
administered (MBq-h/MBq) and DF is a dose factor that depends on the radionuclide used and on 
the spatial relationship between the target and the source organs, and on their tissue compositions. 
The dose factor DF is given as: 
m
wEnk
DF i
Riii


 
where m is the mass of the target organ, ni is the number of i-th nuclear transitions per nuclear 
transformation, Ei is the mean energy of the i-th nuclear transition,  i is the absorbed fraction in the 
target organ of radiation energy Ei emitted from the source organ, wR is the radiation weighting 
factor assigned to the i-th radiation and k is a constant (which value depends on the units of the 
included quantities). 
To calculate the equivalent dose in the main organs delivered from the radiopharmaceuticals 
labelled with each one of the Tc radioisotopes present in the CP-
99m
Tc solution, the number of 
disintegrations of all source organs calculated for each radionuclide and the adult male phantom 
were used as program inputs with both versions of OLINDA/EXM software. Effective dose (ED) 
for each Tc radioisotope was calculated by OLINDA as the tissue-weighted sum of the equivalent 
doses. Total effective dose (EDt) produced by the CP-
99m
Tc was calculated at 5 different times after 
irradiation (6, 8, 10, 12 and 15 h) using the following equation: 
 
where fi is the fraction of total activity corresponding to each radioisotope i and EDi is the effective 
dose contribution per unit of activity from each radioisotope i. The values for fi parameters were 
obtained from the experimental results found in the framework of the TECHN_OSP/LARAMED 
research project on cyclotron-Tc production. The relative activities of 
99m
Tc and the other 
technetium isotopes, obtained after irradiation of 
100
Mo-enriched (99.05%) metallic targets with 
15.7 MeV proton beam for 60 min, were used as reference data
8
. The target irradiation was carried 
out on the model PETtrace 16-9 medical cyclotron, located at St. Orsola-Malpighi Hospital, Nuclear 
Medicine Department (Bologna, Italy). Table 1 shows the average of relative activities of the 
technetium nuclides in the extracted solutions, obtained from 3 experiments and calculated at the 
EOB
8
. Table 2 shows the radionuclide’s impurity limits for human use of sodium pertechnetate, 
reported by the European Pharmacopoeia, version 9.3, and the fraction of the total activity 
corresponding to each Tc-radioisotope calculated for the five time points after EOB studied.  
 
 i iit EDfED
Table 1. Technetium-nuclide relative activities in the extracted solution calculated for EOB (see 
text for irradiation parameters). 
 
Radioisotope     
Physical half-life 
(h) 
Radioactive 
concentration (%) 
99m
Tc 6.01 96.59 ± 0.62 
97m
Tc
 2193.6 0.001130 ± 0.000064 
96
Tc 102.72 0.0273 ± 0.0033 
95
Tc 20 0.1229 ± 0.0243 
95m
Tc 1464 0.00063 ± 0.00013 
94
Tc 4.88 0.1577 ± 0.0367 
94m
Tc 0.87 0.8932 ± 0.3868 
93
Tc 2.75 0.05429 ± 0.01214 
93m
Tc 0.73 2.15 ± 0.09 
 
 
 
Table 2. Radionuclide impurity limits reported by the European Pharmacopoeia, version 9.3, and 
the fraction of the total activity corresponding to each Tc-radioisotope in the extracted solution, 
calculated for five different time points after EOB. 
  
 
3. RESULTS  
The total number of disintegrations in the main source organs depends directly on the 
pharmacokinetics of each complex and on the half-life of the radionuclide.  The calculated values, 
for each Tc-radioisotope after administration of Tc-pertechnetate, Tc-HEDP and Tc-HMPAO 
radiopharmaceuticals are summarized in Table 3. For each radiopharmaceutical, 
97m
Tc and 
95m
Tc 
 Fraction of technetium isotopes contribution to the total activity (%) 
Pharmacopoeia Limit 
99m
Tc 
97m
Tc 
96
Tc 
95
Tc 
95m
Tc 
94
Tc 
94m
Tc 
93
Tc 
93m
Tc
 
 ----- 0.010 0.070 0.070 0.005 0.040 0.02 0.040 0.010 
Time after EOB (h) 
99m
Tc 
97m
Tc 
96
Tc 
95
Tc 
95m
Tc 
94
Tc 
94m
Tc 
93
Tc 
93m
Tc 
0 96.59 0.001 0.027 0.123 0.001 0.158 0.893 0.054 2.154 
6 99.54 0.002 0.054 0.206 0.001 0.139 0.0152 0.025 0.0134 
8 99.53 0.003 0.067 0.242 0.002 0.131 0.0039 0.019 0.0024 
10 99.49 0.004 0.083 0.284 0.002 0.125 0.0010 0.014 0.0004 
12 99.43 0.005 0.104 0.334 0.003 0.118 0.0002 0.011 0.0001 
15 99.31 0.007 0.143 0.425 0.004 0.109 0.0000 0.007 0.0000 
are the radionuclides that produced the highest number of the disintegrations per unit of 
administered activity (see table 3), due to their long half-life.  
Table 3. Calculated number of disintegrations in the source organs per each MBq of 
9x
Tc- 
radiopharmaceuticals administered. 
Source organ 
Number of disintegrations per unit of administered activity (MBq h/MBq) 
99m
Tc 
97m
Tc 
96
Tc 
95
Tc 
95m
Tc 
94
Tc 
94m
Tc 
93
Tc 
93m
Tc
 
Tc-Pertechnetate          
Thyroid 0.037 0.068 0.064 0.052 0.067 0.035 0.015 0.027 0.013 
Salivary gland 0.056 0.101 0.096 0.078 0.101 0.052 0.022 0.041 0.020 
Stomach content 0.179 0.200 0.199 0.193 0.200 0.175 0.111 0.160 0.102 
Stomach wall 0.247 0.288 0.286 0.275 0.288 0.239 0.134 0.212 0.122 
Small intestine content 0.548 0.799 0.779 0.703 0.799 0.510 0.191 0.398 0.166 
Upper large int. walls 0.379 1.506 1.341 0.878 1.501 0.308 0.027 0.156 0.020 
Upper large int. content 0.712 2.586 2.328 1.587 2.579 0.583 0.054 0.303 0.040 
Lower large int. content 0.349 4.737 3.698 1.574 4.708 0.244 0.005 0.079 0.003 
Bladder content 0.342 0.963 0.807 0.554 0.958 0.306 0.063 0.209 0.049 
Others 4.318 28.533 20.711 9.908 28.267 3.678 0.852 2.324 0.725 
Tc-HEDP         
 
Bone 2.953 35.453 21.619 8.119 34.904 2.443 0.425 1.423 0.346 
Kidneys 0.125 0.869 0.553 0.245 0.856 0.113 0.062 0.088 0.060 
Bladder content 1.147 2.151 1.856 1.490 2.139 1.072 0.319 0.833 0.256 
Total body 4.005 41.310 25.492 10.031 40.683 3.448 0.896 2.213 0.777 
Tc-HMPAO         
 
Brain 0.407 6.635 3.580 1.194 6.499 0.335 0.062 0.193 0.052 
Thyroid 0.044 0.356 0.249 0.110 0.353 0.037 0.008 0.022 0.007 
Lung 0.708 8.585 5.226 1.953 8.451 0.587 0.118 0.347 0.100 
Liver 0.505 1.372 1.243 0.890 1.369 0.446 0.131 0.306 0.114 
Gall bladder content 0.097 0.130 0.127 0.118 0.130 0.092 0.039 0.075 0.035 
Stomach wall 0.047 0.736 0.398 0.134 0.721 0.039 0.008 0.023 0.007 
Small intestine wall 0.203 3.170 1.716 0.579 3.106 0.168 0.033 0.099 0.028 
Upper large int. wall 0.066 1.030 0.558 0.188 1.009 0.055 0.011 0.032 0.009 
Lower large int. wall 0.050 0.781 0.423 0.143 0.765 0.041 0.008 0.024 0.007 
Stomach content 0.006 0.007 0.007 0.006 0.007 0.074 0.004 0.005 0.003 
Small intestine content 0.233 0.340 0.331 0.299 0.339 0.189 0.081 0.169 0.071 
Upper large int. content 0.303 1.099 0.989 0.669 1.096 0.216 0.023 0.129 0.017 
Lower large int. content 0.148 2.013 1.572 0.675 2.001 0.091 0.002 0.034 0.001 
Kidneys 0.624 3.082 2.526 1.416 3.066 0.527 0.109 0.320 0.007 
Bladder content 0.546 1.472 1.199 0.818 1.463 0.500 0.134 0.373 0.107 
Others 2.993 24.504 17.147 7.546 24.248 2.515 0.570 1.545 0.488 
 
  
It has been demonstrated that the concentration of Tc-MIBI in the source organs can change 
depending on whether the myocardial perfusion test is carried out in stress or  rest conditions
25
; 
thus, the total number of disintegrations in the main source organs after MIBI administration was 
calculated considering both stress and rest models. Table 4 shows in general, a higher number of 
disintegrations in the source organs when the test was performed in rest conditions because the Tc-
MIBI-concentration in the source organs increases. Muscle and heart are the only organs that 
present a higher number of disintegrations during the myocardial perfusion test in stress conditions.  
 
Table 4. Calculated number of disintegrations in the source organs per each MBq of 
9x
Tc-MIBI 
administered, using both stress and rest models. 
Source organ 
Number of disintegrations per unit of administered activity (MBq h/MBq) 
99m
Tc 
97m
Tc 
96
Tc 
95
Tc 
95m
Tc 
94
Tc 
94m
Tc 
93
Tc 
93m
Tc
 
Tc-MIBI (rest)          
Heart 0.069 0.227 0.195 0.126 0.226 0.061 0.016 0.041 0.014 
Liver 0.674 2.452 2.057 1.264 2.440 0.596 0.192 0.420 0.168 
Gall bladder 0.246 1.213 0.994 0.557 1.207 0.207 0.043 0.126 0.036 
Small intestine content 0.496 0.723 0.705 0.636 0.723 0.462 0.172 0.361 0.150 
Upper large int.  content 0.644 2.340 2.107 1.425 2.334 0.528 0.049 0.274 0.036 
Lower large int. content 0.316 4.287 3.347 1.436 4.261 0.221 0.045 0.072 0.003 
Kidneys 0.653 1.409 1.324 1.047 1.407 0.581 0.156 0.399 0.133 
Bladder content 0.190 0.576 0.498 0.334 0.573 0.168 0.034 0.113 0.027 
Muscles 1.387 6.850 5.613 3.148 6.813 1.170 0.242 0.712 0.204 
Salivary glands 0.104 0.514 0.421 0.236 0.511 0.088 0.018 0.053 0.015 
Thyroids 0.006 0.009 0.008 0.008 0.009 0.006 0.003 0.005 0.002 
Others 3.120 15.412 12.630 7.082 15.330 2.633 0.545 1.602 0.460 
Tc-MIBI (stress) 
         
Heart 0.092 0.303 0.260 0.168 0.302 0.081 0.022 0.055 0.019 
Liver 0.530 2.132 1.774 1.056 2.121 0.463 0.134 0.313 0.116 
Gall bladder 0.202 0.998 0.818 0.459 0.993 0.170 0.035 0.104 0.030 
Small int. content 0.385 0.563 0.548 0.495 0.562 0.359 0.134 0.281 0.117 
Upper large int. cont. 0.501 1.821 1.639 1.108 1.816 0.410 0.038 0.213 0.028 
Lower large int. cont. 0.246 3.335 2.603 1.117 3.314 0.172 0.004 0.056 0.002 
Kidneys 0.466 1.007 0.945 0.748 1.005 0.415 0.111 0.285 0.095 
Bladder content 0.151 0.545 0.463 0.291 0.543 0.131 0.024 0.085 0.019 
Muscles 2.774 13.700 11.227 6.295 13.626 2.340 0.484 1.424 0.409 
Salivary glands 0.069 0.342 0.281 0.157 0.341 0.059 0.012 0.036 0.010 
Thyroids 0.004 0.006 0.006 0.005 0.006 0.004 0.002 0.003 0.002 
Others 2.566 12.672 10.385 5.823 12.605 2.165 0.448 1.317 0.378 
 
Radiopharmaceutical effective doses (ED) calculated for each Tc radioisotope are summarized in 
table 5. The small difference in the effective dose values, obtained with both versions of 
OLINDA/EXM software, is attributable to the divergence in the tissue weighting factors and the 
phantom models used by each version. 
Table 5. Radiopharmaceuticals effective doses calculated using both versions of OLINDA/EXM 
for each Tc radioisotope 
 
Table 6 shows the total effective dose (mSv/MBq) calculated with both software versions, for the 
radiopharmaceuticals prepared with pure 
99m
Tc eluted from a generator (GP-
99m
Tc) and the 
99m
Tc 
produced by the cyclotron at different time points after EOB. The increase in effective dose to the 
patient (in percent), caused by the presence of the other Tc-radionuclides, is also reported in this 
table. 
In general the values of effective dose calculated with version 2.0 of OLINDA/EXM decreased for 
Tc-HEDP and Tc-HMPAO, remained the same for Tc-pertechnetate, and increased for Tc-MIBI, 
compared to those obtained using version 1.1 (Table 6). The difference in effective dose after 
Nuclide 
Tc-radiopharmaceuticals effective doses (mSv/MBq ) 
Tc-Pertechnetate Tc-HEDP Tc-HMPAO Tc-MIBI rest Tc-MIBI stress 
OLINDA/EXM 1.1     
99m
Tc 1.07E-02 6.42E-03 9.25E-03 7.94E-03 6.84E-03 
97m
Tc 1.44E-01 4.45E-02 1.99E-01 1.14E-01 9.01E-02 
96
Tc 4.71E-01 3.71E-01 5.06E-01 4.21E-01 3.83E-01 
95
Tc 8.87E-02 5.55E-02 8.01E-02 7.67E-02 6.94E-02 
95m
Tc 1.90E-01 1.66E-01 2.40E-01 1.63E-01 1.46E-01 
94
Tc 1.13E-01 7.99E-02 9.55E-02 9.14E-02 8.19E-02 
94m
Tc 6.58E-02 3.63E-02 4.54E-02 3.70E-02 2.26E-02 
93
Tc 4.23E-02 3.18E-02 3.33E-02 3.14E-02 2.78E-02 
93m
Tc 1.12E-02 6.73E-03 6.86E-03 5.71E-03 4.79E-03 
OLINDA/EXM 2.0     
99m
Tc 1.07E-02 5.24E-03 8.64E-03 8.09E-03 7.04E-03 
97m
Tc 1.50E-01 3.82E-02 1.88E-01 1.22E-01 1.00E-01 
96
Tc 3.67E-01 3.06E-01 4.37E-01 3.44E-01 3.16E-01 
95
Tc 7.29E-02 4.52E-02 6.97E-02 6.74E-02 6.09E-02 
95m
Tc 1.55E-01 1.39E-01 2.13E-01 1.38E-01 1.25E-01 
94
Tc 1.02E-01 6.31E-02 8.68E-02 8.32E-02 7.46E-02 
94m
Tc 6.92E-02 2.94E-02 3.97E-02 3.54E-02 2.44E-02 
93
Tc 3.95E-02 2.48E-02 3.05E-02 2.87E-02 2.55E-02 
93m
Tc 1.30E-02 6.09E-03 7.05E-03 6.08E-03 5.26E-03 
administration of CP-
99m
Tc and GP-
99m
Tc labelled-radiopharmaceuticals were lower using 
OLINDA/EXM 2.0 except for the case of Tc-HEDP, in which the values remained invariable. All 
radiopharmaceuticals showed greater differences in effective doses after 15 h of EOB, because the 
concentration of impurities increases over the time, as shown in table 2. 
 
Table 6. Total effective dose (EDt) calculated for GP-
99m
Tc and CP-
99m
Tc radiopharmaceuticals 
and percent of patient dose increase (DI) after administration of CP-
99m
Tc radiopharmaceuticals at 
different time points after EOB. 
 
 
Figure 1 shows the contribution (in percentage) of each Tc-radionuclide to the 
radiopharmaceutical’s effective dose at 3 different time points after EOB (8, 10 and 12h), calculated 
with both versions of OLINDA/EXM.  Data for MIBI are reported only for stress condition 
because, in this case, the DI is higher than in rest conditions. As expected, 
96
Tc is the radioisotope 
 
Calculated total effective dose (mSv/MBq ) and  dose increase for each radiopharmaceutical 
OLINDA/EXM 1.1 Tc-Pertechnetate Tc-HEDP Tc-HMPAO Tc-MIBI rest Tc-MIBI stress 
Labelled with GP-
99m
Tc EDt EDt EDt EDt EDt 
 1.07E-02 6.42E-03 9.25E-03 7.94E-03 6.84E-03 
Labelled with CP-
99m
Tc EDt DI (%) EDt DI (%) EDt DI (%) EDt DI (%) EDt DI (%) 
Time after EOB           
6 h 1.13E-02 5.34 6.83E-03 6.44 9.80E-03 5.96 8.43E-03 6.22 7.29E-03 6.53 
8 h 1.13E-02 6.04 6.89E-03 7.31 9.88E-03 6.84 8.50E-03 7.11 7.35E-03 7.48 
10 h 1.14E-02 6.97 6.96E-03 8.47 9.99E-03 7.99 8.59E-03 8.24 7.43E-03 8.69 
12 h 1.16E-02 8.15 7.06E-03 9.92 1.01E-02 9.41 8.71E-03 9.67 7.54E-03 10.19 
15 h 1.18E-02 10.47 7.24E-03 12.80 1.04E-02 12.21 8.93E-03 12.46 7.74E-03 13.14 
OLINDA/EXM 2.0           
Labelled with GP-
99m
Tc EDt EDt EDt EDt EDt 
 1.07E-02 5.24E-03 8.64E-03 8.09E-03 7.04E-03 
Labelled with CP-
99m
Tc EDt DI (%) EDt DI (%) EDt DI (%) EDt DI (%) EDt DI (%) 
Time after EOB           
6 h 1.11E-02 4.40 5.57E-03 6.41 9.12E-03 5.57 8.51E-03 5.19 7.42E-03 5.42 
8 h 1.12E-02 4.92 5.62E-03 7.30 9.19E-03 6.38 8.57E-03 5.90 7.47E-03 6.18 
10 h 1.13E-02 5.64 5.68E-03 8.47 9.28E-03 7.43 8.64E-03 6.83 7.54E-03 7.15 
12 h 1.14E-02 6.56 5.76E-03 9.94 9.40E-03 8.74 8.74E-03 7.98 7.63E-03 8.37 
15 h 1.16E-02 8.37 5.91E-03 12.85 9.62E-03 11.33 8.92E-03 10.25 7.79E-03 10.74 
with greatest contribution to the effective dose, followed by 
95
Tc and 
94
Tc; the contribution of other 
Tc-radioisotopes is quite low, being at least 3 orders of magnitude smaller than the contribution of 
99m
Tc.  
 
 
 Figure 1. Contribution (in percentage) of each Tc-radionuclide to the effective dose of 
radiopharmaceuticals at 3 different time points after EOB (8, 10 and 12h) calculated with both 
versions of OLINDA/EXM. 
 
4. DISCUSSION 
The number of disintegrations in the main source organs calculated for each Tc-radioisotope after 
administration of Tc-pertechnetate, Tc-HEDP and Tc-MIBI are in general agreement with the data 
reported by Hou et al
10
. However, some differences were found. The authors did not consider 3 
important source organs (salivary gland, stomach content and upper large intestine walls) reported 
in the ICRP biokinetic model to calculate the dose produced by Tc-pertechnetate. They also 
underestimated the number of disintegrations for the Tc-MIBI model since liver delay and 
gallbladder uptake were not considered for the calculation. The greatest difference was found in the 
number of disintegrations of the total body calculated with the Tc-HEDP biokinetic model, because 
their calculated values range from half to 9 times less the values reported in table 3. It is not 
possible to determine whether these differences produced a considerable effect on the calculated 
total effective dose, by comparison with the results of the present work, because Hou et al did not 
report the total effective dose values, but rather, the percent of difference between cyclotron and 
reactor-produced technetium
10
.  
In general, low differences between the total effective doses calculated with both versions of the 
OLINDA software were expected, because version 2.0 uses more anatomically-accurate NURBS 
phantoms. Furthermore, some tissue-weighting factor values differ from the version 1.1 (ICRP 60) 
to version 2.0 (ICRP 103), resulting in an increment in the tissue equivalent dose, as in the case of 
Tc-MIBI, where the rise of muscle-weighting factor from 0.005 to 0.01 produced higher total 
effective doses using OLINDA/EXM 2.0 (see Table 6). However, the DI remained within the 10 % 
limit from 6 to 12 h after EOB for all of the radiopharmaceuticals labelled with the CP-
99m
Tc 
studied, when the more accurate version of Olinda/EXM 2.0 was used.  
Table 6 shows that the percent of increase in dose is different for each radiopharmaceutical because 
the biological half-life in each source organ differs among compounds. Therefore, dose calculation 
must be done for each radiopharmaceutical in order to determine the range of time after the EOB in 
which the Tc-radiopharmaceutical can be administered to remain within the 10 % limit of DI. 
The greatest time dependence in the DI contribution from Tc-radionuclides in the studied time 
intervals was found for 
94m
Tc and 
93m
Tc, since their impact on the dose decreases quickly. Although 
these Tc-radionuclides present the highest concentration in the CP-
99m
Tc solution at the EOB, their 
contribution to the dose 6 h later will be minimal due to their short half-life (see Table 2). 
Radionuclides such as 
97m
Tc, 
96
Tc, and 
95m
Tc, having a longer half-life, should instead increase their 
dose contribution over time; however, due to the small concentrations in the reaction mixture, the 
increment is negligible (see fig 1).  
Table 7 compares the increase of the total effective doses for three Tc-radiopharmaceuticals 
calculated from our experimental results, with the theoretical calculations from Hou et al 
10
 using 
the same Isoflex Mo target enriched to 99.05%, irradiated for 3h with a proton beam of 16 MeV. 
Dose contribution of Tc-impurities calculated by Hou also using OLINDA/EXM 1.1 software, is 
higher due to the longer irradiation time. Twelve hours after EOB, the increase in effective dose is 
greater than 10% for Tc-pertechnetate and Tc-MIBI, only Tc-HEDP DI remained under 10%.  
However, this is probably a consequence of the underestimation of the number of Tc-HEDP 
disintegrations in the whole body. Selivanova et al reported a 7.58 % increase in Tc-pertechnetate 
effective dose, assuming an irradiation at 24 MeV for two hours and injection time 6 hours after 
EOB, which is superior to the 5.30% obtained in this work for the same Mo target and injection 
time. This increment is the consequence of a greater production of 
94
Tc, 
95
Tc and 
96
Tc- 
radionuclides at 24 MeV. 
96
Tc was the radioisotope with the highest contribution to the effective dose and is potentially 
detrimental to the image quality, due to its energetic γ rays 8. Thus, the best CP-99mTc method 
should be one that produces the least amount of 
96
Tc. Using a proton beam of 15.7 MeV and an 
enriched Isoflex Mo target (99.05 %) it was found that just  0.0267% of the total activity is related 
to 
96
Tc (see Table 1). Selivanova et al
26
 reported a 
96
Tc concentration in the Tc-final product of 
0.0695%, 0.1478% and 0.1614% using the same type of Mo target and proton beams of 20, 22 and 
24 MeV, respectively. These results demonstrate that the low-energy conventional medical 
cyclotron is preferable, since it produces 
99m
Tc with less concentration of 
96
Tc than medium-energy 
cyclotrons, as preliminary reported in the theoretical study by Esposito et al
6
.  
 
Table 7. Comparison of the increase of total effective dose calculated in this study (15.7 MeV and 
1h irradiation) for three Tc-radiopharmaceuticals with the values reported in the literature by Hou et 
al (16 MeV and 3 h irradiation). 
Irradiation data Radiopharmaceuticals 
15.7 MeV (1 h) Tc-pertechnetate Tc-HEDP Tc-MIBI rest 
Time after EOB     
8 h 5.99 % 7.25 % 7.05 % 
12 h 8.07 % 9.82 % 9.57 % 
16 MeV (3 h)    
Time after EOB     
8 h 8.28 % 7.49 % 9.23 % 
12 h 10.99 % 9.59 % 12.22 % 
 
 
To calculate the maximum patient radiation dose increase after the administration of the CP-
99m
Tc-
radiopharmaceuticals, the total effective dose values were multiplied by the maximum activity used 
in clinical practice for each type of diagnostic radiopharmaceutical. Table 8 shows the maximum 
radiation dose that a patient could receive after the administration of radiopharmaceuticals labelled 
with GP-
99m
Tc and CP-
99m
Tc, assuming the Tc impurity levels in the limits established by the 
European Pharmacopoeia (see table 2) and the Tc impurities obtained in our experimental studies. 
Analysing these values, it is clear that the increment of the dose due to the impurities is minimal. In 
all cases, patient radiation dose is lower than the maximum dose accepted for an imaging study (10 
mSv) and also, than the dose received by patients after the administration of 370 MBq of 
18
FDG 
(7.03 mSv)
17
. 
  
  Table 8. Maximum patient radiation dose after the administration of radiopharmaceuticals labelled 
with technetium from different sources. 
 CONCLUSIONS 
The percent of increase in dose is different for each radiopharmaceutical because the biological 
half-life in each source organ differs among compounds. Therefore, to determine the range of time 
after EOB in which the Tc-solution can be used, it is necessary to perform dosimetric studies with 
the most representative radiopharmaceuticals, not just with Tc-pertechnetate. 
Comparing the results obtained using the data of our target irradiation experiments with the data 
reported by other research groups, it was concluded that the CP-
99m
Tc, produced at lower energy 
(16 MeV) for shorter irradiation time (60 min), shows some advantages. Because, although the 
quantity of 
99m
Tc produced in this way is lower, its radionuclidic purity is higher, and the solution 
can be used for a longer period of time without increasing the patient absorbed dose substantially. 
The patient radiation absorbed dose increase by the contribution of Tc contaminant activity present 
in the cyclotron-
99m
Tc solution, produced by the beam irradiation conditions reported in this work, 
is relatively low. However, its impact should not be underestimated. Based on this data, it was 
concluded that although the concentrations of two radionuclides
 94
Tc and 
95
Tc in the CP-
99m
Tc, is 
outside the limits established by the European Pharmacopoeia for all the time points studied, 
radiopharmaceuticals labelled with this CP-
99m
Tc solution administered from 6 to 12 h after the end 
 
 
 
99m
Tc Source 
Patient radiation dose after 
99m
Tc-radiopharmaceutical administration (mSv) 
Tc-pertechnetate 
(250 MBq) 
Tc-HEDP
 
(1000 MBq) 
Tc-HMPAO
 
(185 MBq)
 
Tc-MIBI rest
 
(740 MBq)
 
Tc-MIBI stress
 
(740 MBq)
 
 OLINDA/EXM version 
GP-
99m
Tc 1.1 2.0 1.1 2.0 1.1 2.0 1.1 2.0 1.1 2.0 
 2.68 2.68 6.42 5.24 1.71 1.60 5.88 5.99 5.06 5.21 
CP-
99m
Tc with the pharmacopoeial limits  
      
 2.79 2.76 6.77 5.52 1.80 1.68 6.17 6.24 5.33 5.43 
CP-
99m
Tc  
         
Time after EOB (h)           
6 2.82 2.78 6.83 5.57 1.81 1.69 6.24 6.30 5.39 5.49 
8 2.84 2.80 6.89 5.62 1.83 1.70 6.29 6.34 5.44 5.53 
10 2.86 2.82 6.96 5.68 1.85 1.72 6.36 6.39 5.50 5.58 
12 2.89 2.84 7.06 5.76 1.87 1.74 6.44 6.46 5.58 5.64 
of bombardment could be used in routine nuclear medicine diagnostic studies because, the dose 
increment remained within the 10% limit.  
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